试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-03-24
Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology
编号:NCT03740243登记状态:入组前撤回企业 / 申办者:Stony Brook University
药物 / 成分:Buprenorphine/naloxone、Buprenorphine
登记的停止原因(原文):No enrollment
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-03-24
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection
编号:NCT04290858登记状态:入组前撤回企业 / 申办者:Xijing Hospital
药物 / 成分:Nitric Oxide
登记的停止原因(原文):New coordinating center has been defined (Massachusetts General Hospital)
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-03-23
Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore
编号:NCT02569827登记状态:入组前撤回企业 / 申办者:Singapore General Hospital
药物 / 成分:Celgosivir、Modipafant 50mg、Placebo、Modipafant 100mg
登记的停止原因(原文):The investigational drug celgosivir will not be developed due to lack of VC funding.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-03-20
Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection
编号:NCT02346617登记状态:入组前撤回企业 / 申办者:Yae-Jean Kim
药物 / 成分:IFN-γ positive selected T-cells
登记的停止原因(原文):Due to the KoreaFDA issue
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-03-20
MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
编号:NCT03986086登记状态:入组前撤回企业 / 申办者:Nelson Chao
药物 / 成分:MPH966、Placebo
登记的停止原因(原文):Lack of Funding
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-03-20
Treatment for Cognitive Impairment in Depression
编号:NCT04317001登记状态:入组前撤回企业 / 申办者:Stanford University
药物 / 成分:Modafinil、Placebo
登记的停止原因(原文):Researcher leading the study moved institutions study not feasible
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-03-19
A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
编号:NCT02713984登记状态:入组前撤回企业 / 申办者:Zhi Yang
药物 / 成分:Anti-HER2 CAR-T
登记的停止原因(原文):Reform CAR structure due to safety consideration
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-03-19
Small-Volume, Patient-Specific, Balanced Hypertonic Fluid Protocol Validation
编号:NCT03330704登记状态:入组前撤回企业 / 申办者:Stanford University
药物 / 成分:3% Sodium Chloride、23.4% Sodium Chloride、8.4% Sodium Bicarbonate
登记的停止原因(原文):lack of eligible study participants
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-03-18
The Effects of Stromal Vascular Fraction and Mesenchymal Stem Cells as Intra-articular Injection in Knee Joint Osteoarthritis
编号:NCT03164083登记状态:入组前撤回企业 / 申办者:SCARM Institute, Tabriz, Iran
药物 / 成分:Mesenchymal stem cell、Placebo
登记的停止原因(原文):not approved by sponsor
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-03-18
Same-Day Treatment With Genvoya vs. EFV/TDF/3TC
编号:NCT03405194登记状态:入组前撤回企业 / 申办者:Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
药物 / 成分:Elvitegravir, Cobicistat, TAF, FTC、Efavirenz, TDF, and 3TC
登记的停止原因(原文):Haiti gained access to dolutegravir as first-line ART, so we cancelled the study before any patient was enrolled (we didn't want SOC group to receive EFV)
查看官方原始记录 ↗